Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

NCT05020249 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT05020249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05020249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Completed
Start date
September 27, 2021
Completion date
September 6, 2022
Enrollment
47 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe plaque psoriasis